[Editor’s Note: this piece was co-authored by Hari Kumar of San Diego-based Amira Pharmaceuticals.] The benefits of partnerships between emerging biotech companies and major drug developers are numerous and well known. The smaller biotech company gets cash to support its innovative R&D, and the Big Pharma company gets hot new patented drug candidates to replace … Continue reading “How Biotechs Can Stand Out in the Competition for a Big Pharma Partnership”
Author: Peppi Prasit
Peppi Prasit is the founder of Inception Sciences. Previously, he was the co-founder and chief scientific officer of San Diego-based Amira Pharmaceuticals. Dr. Prasit has more than 20 years of experience in pharmaceutical research and management serving in various positions with Merck Frosst Canada and more recently at Merck San Diego. During this time, he played a pivotal role in the discovery of multiple marketed drugs. In 2005, he co-founded Amira Pharmaceuticals. Amira is a small-molecule pharmaceutical company focused on the discovery and early development of new drugs to treat inflammatory diseases. The Amira team is building on unparalleled insights into bioactive lipid pathways, a complex signaling process controlling many conditions including asthma, chronic obstructive pulmonary disease, idiopathic pulmonary fibrosis and cardiovascular disease. Dr. Prasit received his B.Sc. from UCL, London University, and his Ph.D. from Victoria University of Wellington in New Zealand and served as a postdoctoral fellow at Princeton University.